Maximilian Stich

Maximilian Stich

Auto-generated profile, based on publicly available information

Maximilian Stich

Department of Pediatrics I, Heidelberg University, Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
HRHanna Renk
Hanna Renk
ADAlex Dulovic
Alex Dulovic
ASAlina Seidel
Alina Seidel
MBMatthias Becker
Matthias Becker
DFDorit Fabricius
Dorit Fabricius
RERoland Elling
Roland Elling
The quality and persistence of children’s humoral immune response following SARS-CoV-2 infection remains largely unknown but will be crucial to guide pediatric SARS-CoV-2 vaccination programs. Here, we examine 548 children and 717 adults within 328 households with at least one member with a previous laboratory-confirmed SARS-CoV-2 infection. We assess serological response at 3–4 months and 11–12 months after infection using a bead-based multiplex immunoassay for 23 human coronavirus antigens including SARS-CoV-2 and its Variants of Concern (VOC) and endemic human coronaviruses (HCoVs), and additionally by three commercial SARS-CoV-2 antibody assays. Neutralization against wild type SARS-CoV-2 and the Delta VOC are analysed in a pseudotyped virus assay. Children, compared to adults, are five times more likely to be asymptomatic, and have higher specific antibody levels which persist longer (96.2% versus 82.9% still seropositive 11–12 months post infection). Of note, symptomatic and asymptomatic infections induce similar humoral responses in all age groups. SARS-CoV-2 infection occurs independent of HCoV serostatus. Neutralization responses of children and adults are similar, although neutralization is reduced for both against the Delta VOC. Overall, the long-term humoral immune response to SARS-CoV-2 infection in children is of longer duration than in adults even after asymptomatic infection.

22 September 2022 in EBioMedicine
Verified
Journal Article
Open access
AHAnneke Haddad
Anneke Haddad
AJAleš Janda
Aleš Janda
HRHanna Renk
Hanna Renk
MSMaximilian Stich
Maximilian Stich
PFPauline Frieh
Pauline Frieh
RERoland Elling
Roland Elling
Long COVID in children and adolescents remains poorly understood due to a lack of well-controlled studies with long-term follow-up. In particular, the impact of the family context on persistent symptoms following SARS-CoV-2 infection remains unknown. We examined long COVID symptoms in a cohort of infected children, adolescents, and adults and their exposed but non-infected household members approximately 1 year after infection and investigated clustering of persistent symptoms within households. 1267 members of 341 households (404 children aged <14 years, 140 adolescents aged 14-18 years and 723 adults) were categorized as having had either a SARS-CoV-2 infection or household exposure to SARS-CoV-2 without infection, based on three serological assays and history of laboratory-confirmed infection. Participants completed questionnaires assessing the presence of long COVID symptoms 11-12 months after infection in the household using online questionnaires. The prevalence of moderate or severe persistent symptoms was statistically significantly higher in infected than in exposed women (36.4% [95% CI: 30.7–42.4%] vs 14.2% [95% CI: 8.7–21.5%]), infected men (22.9% [95% CI: 17.9–28.5%] vs 10.3% [95% CI: 5.8–16.9%]) and infected adolescent girls (32.1% 95% CI: 17.2–50.5%] vs 8.9% [95%CI: 3.1–19.8%]). However, moderate or severe persistent symptoms were not statistically more common in infected adolescent boys aged 14–18 (9.7% [95% CI: 2.8–23.6%] or in infected children <14 years (girls: 4.3% [95% CI: 1.2–11.0%]; boys: 3.7% [95% CI: 1.1–9.6%]) than in their exposed counterparts (adolescent boys: 0.0% [95% CI: 0.0–6.7%]; girls < 14 years: 2.3% [95% CI: 0·7–6·1%]; boys < 14 years: 0.0% [95% CI: 0.0–2.0%]). The number of persistent symptoms reported by individuals was associated with the number of persistent symptoms reported by their household members (IRR=1·11, p=·005, 95% CI [1.03–1.20]). In this controlled, multi-centre study, infected men, women and adolescent girls were at increased risk of negative outcomes 11-12 months after SARS-CoV-2 infection. Amongst non-infected adults, prevalence of negative outcomes was also high. Prolonged symptoms tended to cluster within families, suggesting family-level interventions for long COVID could prove useful. Ministry of Science, Research and the Arts, Baden-Württemberg, Germany.

28 November 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
EJEva-Maria Jacobsen
Eva-Maria Jacobsen
DFDorit Fabricius
Dorit Fabricius
MCMagdalena Class
Magdalena Class
FTFernando Topfstedt
Fernando Topfstedt
RLRaquel Lorenzetti
Raquel Lorenzetti
AJAleš Janda
Aleš Janda
The COVID-19 course and immunity differ in children and adults. We analyzed immune response dynamics in 28 families up to 12 months after mild or asymptomatic infection. Unlike adults, the initial response is plasmablast-driven in children. Four months after infection, children show an enhanced specific antibody response and lower but detectable spike 1 protein (S1)-specific B and T cell responses than their parents. While specific antibodies decline, neutralizing antibody activity and breadth increase in both groups. The frequencies of S1-specific B and T cell responses remain stable. However, in children, one year after infection, an increase in the S1-specific IgA class switch and the expression of CD27 on S1-specific B cells and T cell maturation are observed. These results, together with the enhanced neutralizing potential and breadth of the specific antibodies, suggest a progressive maturation of the S1-specific immune response. Hence, the immune response in children persists over 12 months but dynamically changes in quality, with progressive neutralizing, breadth, and memory maturation. This implies a benefit for booster vaccination in children to consolidate memory formation.

21 November 2022 in Pediatric Nephrology
Verified
Journal Article
Open access
PDF file
MSMaximilian Stich
Maximilian Stich
VCVeronica Di Cristanziano
Veronica Di Cristanziano
BTBurkhard Tönshoff
Burkhard Tönshoff
LWLutz T Weber
Lutz T Weber
JDJörg Dötsch
Jörg Dötsch
SHSophie Haumann
Sophie Haumann
Background: Data on humoral immune response to standard COVID-19 vaccination are scarce in adolescent patients and lacking for children below 12 years of age with chronic kidney disease including kidney transplant recipients. Methods: We therefore investigated in this retrospective two-center study (DRKS00024668; registered 23.03.2021) the humoral immune response to a standard two-dose mRNA vaccine regimen in 123 CKD patients aged 5–30 years. A live-virus assay was used to assess the serum neutralizing activity against the SARS-CoV-2 omicron (BA.1) variant. Results: Children aged 5–11 years had a comparable rate and degree of immune response to adolescents despite lower vaccine doses (10 µg vs. 30 µg BNT162b2). Treatment with two (odds ratio 9.24) or three or more (odds ratio 17.07) immunosuppressants was an independent risk factor for nonresponse. The immune response differed significantly among three patient cohorts: 48 of 77 (62.3%) kidney transplant recipients, 21 of 26 (80.8%) patients on immunosuppressive therapy, and 19 of 20 (95.0%) patients with chronic kidney disease without immunosuppressive therapy responded. In the kidney transplant recipients, immunosuppressive regimens comprising mycophenolate mofetil, an eGFR of < 60 mL/min/1.73 m2, and female sex were independent risk factors for nonresponse. Two of 18 (11.1%) and 8 of 16 (50.0%) patients with an anti-S1-RBD IgG of 100–1411 and > 1411 BAU/mL, respectively, showed a neutralization activity against the omicron variant. Conclusion: A standard mRNA vaccine regimen in immunosuppressed children and adolescents with kidney disease elicits an attenuated humoral immune response with effective live virus neutralization against the omicron variant in approximately 10% of the patients, underlying the need for omicron-adapted vaccination. Graphical

12 December 2025 in Blood Advances
Verified
Journal Article
Open access
SBSudipta Biswas
Sudipta Biswas
ZZZeinab Albadry M. Zahran
Zeinab Albadry M. Zahran
XGXiaorong Gu
Xiaorong Gu
LCLisa Cardone
Lisa Cardone
RMRemuna Marti
Remuna Marti
YSYogen Saunthararajah
Yogen Saunthararajah
Acute myeloid leukemias (AML) containing TP53 (p53) mutations are routinely treated with decitabine or 5-azacytidine, which deplete DNA methyltransferase 1 (DNMT1; ie, hypomethylating agents [HMA]). Unfortunately, resistance/relapse, characterized by preserved DNMT1, is rapid. HMA are pyrimidine analogs, and to deplete DNMT1, must compete with endogenous pyrimidines. These were substantially increased in HMA-resistant vs parental AML cells, together with upregulation of CAD (carbamoyl-phosphate-synthetase-2/aspartate transcarbamylase/dihydroorotase) that rate limits de novo pyrimidine synthesis. Moreover, TP53-mutated AML appeared primed for such resistance, with higher baseline CAD. Pyrimidine synthesis can be depowered with the B-cell lymphoma 2 (BCL2) inhibitor venetoclax to release BCL-2–associated X protein (BAX) to depolarize mitochondrial membranes. However, BAX, a p53 target gene, was substantially less expressed in TP53-mutated vs wild-type TP53 cells, and venetoclax impacts were correspondingly limited. Alternatively, pyrimidine synthesis can be inhibited directly at dihydroorotate dehydrogenase (DHODH) using the clinical drug teriflunomide. Contrasting with venetoclax, teriflunomide decreased pyrimidine levels several-fold, restored DNMT1 depletion, and cytoreduced HMA-resistant TP53-mutated AML cells via p53/apoptosis-independent terminal-differentiation. This noncytotoxic pathway preserved viability and proliferation of normal hematopoietic stem/progenitor cells (NHSPCs). Inhibiting pyrimidine synthesis triggered compensatory pyrimidine salvage, such that schedules for teriflunomide combination with HMA, which are taken up by salvage, mattered. In mice with TP53-mutated AML, teriflunomide scheduled the day before HMA was more efficacious than same-day or day-after schedules. Chronic teriflunomide exposure paradoxically increased pyrimidines via sustained compensatory salvage, conferring resistance rather than sensitivity to HMA. In sum, DNMT1 and DHODH targeting, administered by timed, intermittent (metronomic) schedules, can circumvent genetic resistance caused by TP53 mutations and adaptive resistance caused by metabolic homeostasis, without cytotoxicity to HSPCs.

26 October 2022 in Pediatrics
Verified
Journal Article
Open access
PDF file
MSMaximilian Stich
Maximilian Stich
LBLouise Benning
Louise Benning
CSClaudius Speer
Claudius Speer
SGSven F. Garbade
Sven F. Garbade
MBMarie Bartenschlager
Marie Bartenschlager
BTBurkhard Tönshoff
Burkhard Tönshoff
Long-term data on the humoral immune response and cross-neutralization against variants of concern in children more than one year after SARS-CoV-2 infection are currently missing and urgently needed in order to predict the likelihood of reinfections and guide vaccination strategies.